Trinity Biotech plc

About Trinity Biotech plc

Trinity Biotech plc is a public company focused on the development, manufacture, and marketing of clinical diagnostic products.

Products & Services

Premier Resolution:A superior HPLC analyser for thalassemia and haemoglobin variant detection.

Bartels(r) FlexTrans™ Transport Medium:Transport medium to suppress microbial contamination during specimen transport.

Uni-Gold™ HIV Complete:Single-use immunoassay for rapid detection of antibodies to HIV-1 and HIV-2 in serum, plasma, or whole blood.

Point of Care:Diagnostic solutions for immediate testing at the point of care.

Infectious Disease:Products for the detection and diagnosis of infectious diseases.

Haemoglobins:Testing solutions for haemoglobin-related conditions.

Autoimmune:Diagnostic products for autoimmune disorders.

Clinical Chemistry:Tools and reagents for clinical chemistry analysis.

Urinalysis:Products for urine testing and analysis.

Premier HB9210 HPLC analyser (thalassemia and haemoglobin variant detection)

Flextrans Transport Medium

Uni-Gold HIV Complete (HIV-1/HIV-2 antibody immunoassay)

Specialties

Clinical Diagnostics Point of Care Testing Infectious Disease Diagnostics Haemoglobin Testing Autoimmune Diagnostics Clinical Chemistry Urinalysis Preeclampsia Testing Continuous Glucose Monitoring (CGM) AI Wearable Technology Point-of-care testing Infectious disease diagnostics Haemoglobin analysis Autoimmune diagnostics Clinical chemistry Reference laboratory services

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Equity Financing T: - FT: Equity Financing	A: 25000000 MR: - FA: 25 million FAN: 25000000	D: 2026-02-25 FD: 2026-02-25	1 investors
2	RT: Debt T: - FT: Debt	A: 4000000 MR: - FA: $4m FAN: 4000000	D: 2025-02-28 FD: 2025-02-28	1 investors
3	RT: Debt T: - FT: Debt	A: 5500000 MR: - FA: approximately $5.5 million FAN: 5500000	D: 2024-12-24 FD: 2024-12-24	1 investors
4	RT: Debt T: - FT: Debt	A: 5000000 MR: - FA: $5,000,000 FAN: 5000000	D: 2023-02-22 FD: 2023-02-22	1 investors

Equity Financing Latest

2026-02-25

$25.0M

1 investor (Pro only)

Debt 2025-02-28

$4.0M

Debt 2024-12-24

$5.5M

View 3 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

No team data available

Team information is not yet available for this company

Recent News